Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442918 | 0.92 | LMNA (0.52) | TP53NPC1PLA2G10ELANELMNA | |
| SCHEMBL5442993 | 0.91 | TP53 (0.47) | TP53NPC1PLA2G10ELANELMNA | |
| SCHEMBL5434662 | 0.89 | PLA2G10 (0.51) | TP53PLA2G10ELANELMNACCR1 | |
| SCHEMBL5435540 | 0.89 | PLA2G10 (0.50) | TP53PLA2G10ELANEMEN1KMT2A | |
| SCHEMBL5435796 | 0.87 | CCR1 (0.54) | PLA2G10ELANEMEN1KMT2ALMNA | |
| SCHEMBL5441836 | 0.86 | ELANE (0.54) | PLA2G10ELANEMEN1KMT2ALMNA | |
| SCHEMBL5451795 | 0.86 | GAA (0.50) | TP53NPC1PLA2G10MAPTELANE | |
| SCHEMBL5438601 | 0.86 | LMNA (0.55) | PLA2G10MAPTELANEMEN1KMT2A | |
| SCHEMBL5434616 | 0.85 | PLA2G10 (0.48) | PLA2G10ELANECCR1 | |
| SCHEMBL5434666 | 0.83 | ELANE (0.55) | NPC1PLA2G10MAPTELANEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, MPO | TP53 2493/4885NPC1 1968/4885PLA2G10 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.